in the news/ businesswire.com
Sphere Fluidics Begins Work With Partners on 3DSecret Program to Investigate Mechanisms of Metastasis in Cancer
3DSecret funded by European Innovation Council’s Pathfinder Open 2022, established under the EU Horizon Europe program
Consortium to leverage novel microfluidic technology to culture 3D cancer models for multi-parametric analysis, to inform cancer diagnostic and therapeutic development
CAMBRIDGE, England--(BUSINESS WIRE) Sphere Fluidics, a company developing single-cell analysis systems underpinned by its patented picodroplet technology, today announced its involvement in 3DSecret, a four-year research project funded through the European Innovation Council’s (EIC) Pathfinder Open 2022, established under Horizon Europe, the EU’s key funding program for research and innovation. Coordinated by the International Iberian Nanotechnology Laboratory (INL), the consortium has been awarded €3.4M and aims to develop novel technologies to investigate the stochastic patterns behind metastasis at the single-cell level, to predict cancer evolution.
“The 3DSecret project, besides having the potential to unlock hidden mechanisms behind metastasis, will provide bleeding tech breakthrough developments to the fields of microfluidics, single-cell studies, sequencing and AI applied to health.”